445 related articles for article (PubMed ID: 18654765)
1. Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).
van Diepen H; Schlicker E; Michel MC
Naunyn Schmiedebergs Arch Pharmacol; 2008 Oct; 378(4):345-69. PubMed ID: 18654765
[TBL] [Abstract][Full Text] [Related]
2. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid CB
Chen W; Liu H; Guan H; Xue N; Wang L
Eur J Pharmacol; 2017 Nov; 814():232-239. PubMed ID: 28844874
[TBL] [Abstract][Full Text] [Related]
4. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.
Martín-García E; Burokas A; Martín M; Berrendero F; Rubí B; Kiesselbach C; Heyne A; Gispert JD; Millán O; Maldonado R
J Neurochem; 2010 Mar; 112(5):1338-13351. PubMed ID: 20028452
[TBL] [Abstract][Full Text] [Related]
5. Intra-accumbens rimonabant is rewarding but induces aversion to cocaine in cocaine-treated rats, as does in vivo accumbal cannabinoid CB1 receptor silencing: critical role for glutamate receptors.
Ramiro-Fuentes S; Ortiz O; Moratalla R; Fernandez-Espejo E
Neuroscience; 2010 May; 167(2):205-15. PubMed ID: 20167255
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.
Kangas BD; Delatte MS; Vemuri VK; Thakur GA; Nikas SP; Subramanian KV; Shukla VG; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Mar; 344(3):561-7. PubMed ID: 23287700
[TBL] [Abstract][Full Text] [Related]
7. Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system.
Pfitzer T; Niederhoffer N; Szabo B
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jan; 371(1):9-17. PubMed ID: 15660243
[TBL] [Abstract][Full Text] [Related]
8. A method for parallel solid-phase synthesis of iodinated analogues of the CB1 receptor inverse agonist rimonabant.
Spivey AC; Tseng CC; Jones TC; Kohler AD; Ellames GJ
Org Lett; 2009 Oct; 11(20):4760-3. PubMed ID: 19778010
[TBL] [Abstract][Full Text] [Related]
9. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
[TBL] [Abstract][Full Text] [Related]
10. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
11. Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.
Lange JH; van Stuivenberg HH; Coolen HK; Adolfs TJ; McCreary AC; Keizer HG; Wals HC; Veerman W; Borst AJ; de Looff W; Verveer PC; Kruse CG
J Med Chem; 2005 Mar; 48(6):1823-38. PubMed ID: 15771428
[TBL] [Abstract][Full Text] [Related]
12. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
Doggrell SA
Expert Opin Investig Drugs; 2005 Mar; 14(3):339-42. PubMed ID: 15833065
[No Abstract] [Full Text] [Related]
13. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103
[TBL] [Abstract][Full Text] [Related]
14. Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Aug; 56(2):132-9. PubMed ID: 17574859
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
Li F; Fang Q; Liu Y; Zhao M; Li D; Wang J; Lu L
Eur J Pharmacol; 2008 Jul; 589(1-3):122-6. PubMed ID: 18534572
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle.
Baldassano S; Serio R; Mule' F
Eur J Pharmacol; 2008 Mar; 582(1-3):132-8. PubMed ID: 18234188
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.
Reggio PH
Curr Pharm Des; 2003; 9(20):1607-33. PubMed ID: 12871061
[TBL] [Abstract][Full Text] [Related]
18. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.
Erdozain AM; Diez-Alarcia R; Meana JJ; Callado LF
Biochem Pharmacol; 2012 Jan; 83(2):260-8. PubMed ID: 22093909
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.
Bátkai S; Pacher P; Járai Z; Wagner JA; Kunos G
Am J Physiol Heart Circ Physiol; 2004 Aug; 287(2):H595-600. PubMed ID: 15059774
[TBL] [Abstract][Full Text] [Related]
20. Computational Prediction and Biochemical Analyses of New Inverse Agonists for the CB1 Receptor.
Scott CE; Ahn KH; Graf ST; Goddard WA; Kendall DA; Abrol R
J Chem Inf Model; 2016 Jan; 56(1):201-12. PubMed ID: 26633590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
